【レポートの概要（一部）】
1. Report Overview
1.1 Overview of the Top Biosimilar Drug Manufacturers
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analytical Study
1.5 Who is This Report For?
1.6 Methodology
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Visiongain Reports
1.9 About Visiongain
2. Biosimilar Drugs: World Market Forecast, 2016-2026
2.1 Introduction to Biologics and Biosimilars
2.1.1 Biologic Drugs Definition and Overview
2.1.2 Biosimilars Drugs Definition and Overview
2.1.3 How do Biosimilars Differ from Generics?
2.2 The World Biosimilar Market, 2015-2026
2.3 Overall World Biosimilars Revenue Forecast, 2016-2026
2.4 Biosimilars – Realising their Potential, Market Drivers
2.4.1 Biosimilar Approval Pathways and Regulations
2.4.2 Emerging Markets for Biosimilars
2.4.3 Start-up Pressure on Market Leaders
2.4.4 The Patent Cliff for Biologics
2.5 Biosimilars: Market Restraints
2.5.1 Market Fragmentation for Biosimilar Products
2.5.2 Innovative Biologics – Rendering Biosimilars Useless?
2.5.3 Biobetters – A Growing Threat
3. Leading Biosimilar Products: Overview, 2016
3.1 Humira: Product Overview
3.1.1 Adalimumab Biosimilars – Zydus Cadila
3.1.2 Adalimumab Biosimilars – Amgen-Actavis
3.1.3 Adalimumab Biosimilars – Sandoz
3.1.4 Adalimumab Biosimilars – Momenta Pharmaceuticals
3.1.5 Adalimumab Biosimilars – Pfizer
3.1.6 Adalimumab Biosimilars – Boehringer Ingelheim
3.2 Remicade: Product Overview
3.2.1 Infliximab Biosimilar – Epirus Pharmaceuticals & Ranbaxy
3.2.2 Infliximab Biosimilar – Celltrion & Hospira & Alvogen
3.3 Enbrel: Product Overview
3.3.1 Etanercept Biosimilar – Cipla & Shanghai CP Guojian
3.3.2 Etanercept Biosimilar – Daiichi Sankyo & Coherus Biosciences
3.4 Aranesp: Product Overview
3.4.1 Darbepoetin Alpha Biosimilar – Dr. Reddy’s Laboratories
3.4.2 Darbepoetin Alpha Biosimilar – Cipla & Hetero Drugs Limited
3.4.3 Darbepoetin Alpha Biosimilar – Hospira
3.5 Rituxan: Product Overview
3.5.1 Rituximab Biosimilar – Sandoz
3.5.2 Rituximab Biosimilar – Amgen
3.5.3 Rituximab Biosimilar – Boehringer Ingelheim
3.5.4 Rituximab Biosimilar – Dr. Reddy’s Laboratories
3.5.5 Rituximab Biosimilar – Pfizer
3.5.6 Rituximab Biosimilar – Difficulties Seen in Trials
4. Leading Biosimilar Manufacturers in the United States, Western Europe and Israel, 2016
4.1 Sandoz – Company Overview & Analysis
4.1.1 Sandoz Biosimilar Products
4.1.2 Sandoz Biosimilars Market Forecast, 2016-2026
4.1.3 Sandoz Biosimilars R&D Pipeline & Future Outlook
4.1.3.1 GP2017 – Adalimumab Biosimilar
4.1.3.2 GP2015 – Etanercept Biosimilar
4.1.3.3 GP2013 – Rituximab Biosimilar
4.1.3.4 HX575 – Epoetin-alfa Biosimilar
4.1.3.5 EP2006 – Zarzio (Filgrastim Biosimilar)
4.2 Teva Pharmaceuticals – Company Overview & Analysis
4.2.1 Teva Biosimilar Products
4.2.2 Teva Biosimilar Market Forecast, 2016-2026
4.2.3 Teva Biosimilar Pipeline & Future Outlook
4.3 Hospira – Company Overview & Analysis
4.3.1 Hospira Biosimilar Products
4.3.2 Hospira Biosimilars Pipeline & Future Strategies
4.3.2.1 Retacrit
4.3.2.2 Celltrion Partnerships
4.3.2.3 NovaQuest Partnership
4.4 STADA Arzneimittel – Company Overview & Analysis
4.4.1 STADA Biosimilar Products
4.4.2 STADA Biosimilars Pipeline & Future Outlook
4.4.2.1 Biosimilar Pegfilgrastim
4.4.2.2 Biosimilar Rituximab
4.4.2.3 Biosimilar Teriparatide
4.5 Mylan – Company Biosimilar & Analysis
4.5.1 Mylan Biosimilar Products
4.5.2 Mylan Biosimilar Market Forecast, 2016-2026
4.5.3 Mylan Biosimilars Pipeline & Future Outlook
4.5.3.1 Mylan and Momenta – Biosimilars Product Development Programme
4.5.3.2 Biosimilar Insulin Glargine
4.5.3.3 A Series of Biosimilar Monoclonal Antibodies
4.5.3.4 Biosimilar Insulin Lispro & Aspart
4.6 Other Biosimilars Companies in the US
4.6.1 Impax Laboratories Inc. – Company Overview & Analysis
4.6.2 Bristol-Myers Squibb – Company Overview & Analysis
4.6.3 Merck & Co. – Company Overview & Analysis
4.6.4 Eli Lilly – Company Overview & Analysis
4.7 Other Biosimilars Companies in Europe
4.7.1 BioXpress Therapeutics – Company Overview & Analysis
4.7.2 Medice Arzneimittel Pütter GmbH & Co. KG – Company Overview & Analysis
4.7.3 Finox Biotech – Company Overview & Analysis
4.7.4 Actavis – Company Overview & Analysis
5. Leading Biosimilar Manufacturers in China, 2016
5.1 S3Bio – Company Overview & Analysis
5.1.1 3SBio Biosimilar Products
5.1.2 3SBio Biosimilars Market Forecast, 2016-2026
5.1.3 3SBio Biosimilars Pipeline & Future Outlook
5.1.3.1 Second-generation rhEPO products
5.1.3.2 Nadroparin Calcium
5.2 Qilu Pharmaceutical – Company Overview & Analysis
5.2.1 Qilu Pharmaceutical Biosimilar Products
5.2.2 Qilu Pharmaceutical Biosimilars Pipeline & Future Outlook
5.2.2.1 Extensive Pipeline Developments
5.2.2.2 Etanercept Biosimilar
5.2.2.3 Other Biosimilars in Pipeline
5.3 Shanghai Fosun Pharmaceuticals – Company Overview & Analysis
5.3.1 Shanghai Fosun Pharmaceuticals Biosimilar Products
5.3.2 Shanghai Fosun Pharmaceuticals Biosimilars Pipeline & Future Strategy
5.3.2.1 Trastuzumab Biosimilar
5.3.2.2 Rituximab Biosimilar
5.3.2.3 Acquisitions and Investments
5.4 Tonghua Dongbao – Company Overview & Analysis
5.4.1 Tonghua Dongbao Biosimilar Products
5.4.2 Tonghua Dongbao Biosimilars Pipeline & Future Strategies
5.4.2.1 Biosimilar Insulin Analogues
5.4.2.2 Investments in New Production Plant
5.5 Beijing ShuangLu Pharmaceuticals – Company Overview & Analysis
5.5.1 Beijing ShuangLu Pharmaceuticals Biosimilar Products
5.5.2 Beijing ShuangLu Pharmaceutical Biosimilars Pipeline & Future Outlook
5.6 Other Biosimilars Companies in China
5.6.1 Shanghai CP Guojian – Company Overview & Analysis
5.6.2 Zhejiang Hisun – Company Overview & Analysis
5.6.3 Innovent Biologics – Company Overview & Analysis
5.6.4 Shanghai Celgen Biopharmaceutical – Company Overview & Analysis
6. Leading Biosimilar Manufacturers in India, 2016
6.1 Biocon – Company Overview & Analysis
6.1.1 Biocon Biosimilar Products
6.1.2 Biocon Biosimilars Market Forecast, 2016-2026
6.1.3 Biocon Biosimilars Pipeline & Future Outlook
6.1.3.1 Biosimilar Bevacizumab
6.1.3.2 Biosimilar Adalimumab
6.1.3.3 Biosimilar Pegfilgrastim
6.1.3.4 Biosimilar Trastuzumab
6.1.3.5 Biosimilar Etanercept
6.1.3.6 Biosimilar Recombinant Human Insulin
6.1.3.7 Biosimilar Insulin Glargine
6.1.3.8 Other Biosimilar Insulin
6.2 Dr. Reddy’s Laboratories – Company Overview & Analysis
6.2.1 Dr. Reddy’s Laboratories Biosimilar Products
6.2.2 Dr. Reddy’s Laboratories Biosimilars Pipeline & Future Outlook
6.2.2.1 Merck Serono Collaboration
6.2.2.2 Increasing Focus on Emerging Markets
6.3 Wockhardt – Company Overview & Analysis
6.3.1 Wockhardt Biosimilar Products
6.3.2 Wockhardt Biosimilars Pipeline & Future Outlook
6.4 Zydus Cadila – Company Overview & Analysis
6.4.1 Zydus Cadila Biosimilar Products
6.4.2 Zydus Cadila Biosimilars Pipeline & Future Outlook
6.4.2.1 Biosimilar Interferon beta-1b
6.4.2.2 Oncology Biosimilars
6.4.2.3 Inflammation Biosimilars
6.4.2.4 Thrombolytic Biosimilars
6.4.2.5 Fertility Biosimilars
6.5 Ranbaxy – Company Overview & Analysis
6.5.1 Ranbaxy Biosimilar Products
6.5.2 Ranbaxy Biosimilars Pipeline & Future Outlook
6.6 Reliance Life Sciences – Company Overview & Analysis
6.6.1 Reliance Life Sciences Biosimilar Products
6.6.2 Reliance Life Sciences Biosimilars Pipeline & Future Outlook
6.7 Intas Biopharmaceuticals – Company Overview & Analysis
6.7.1 Intas Biopharmaceuticals Biosimilar Products
6.7.2 Intas Biopharmaceuticals Biosimilars Pipeline & Future Outlook
6.7.2.1 Biosimilar Pegylated Interferon
6.7.2.2 Biosimilar Etanercept
6.7.2.3 Biosimilar Ranibizumab
6.7.2.4 Overseas Opportunities
6.8 Other Indian Biosimilars Companies
6.8.1 Emcure Pharmaceuticals – Company Overview & Analysis
6.8.2 Shreya Life Sciences – Company Overview & Analysis
6.8.3 Cipla – Company Overview & Analysis
6.8.4 Shantha Biotechnics – Company Overview & Analysis
7. Leading Biosimilar Manufacturers in Latin America, 2016
7.1 Probiomed – Company Overview & Analysis
7.1.1 Probiomed Biosimilar Products
7.1.2 Probiomed Biosimilars Pipeline & Future Strategies
7.2 Biosidus – Company Overview & Analysis
7.2.1 Biosidus Biosimilar Products
7.2.2 Biosidus Biosimilars Pipeline & Future Strategies
7.3 Amega Biotech – Company Overview and Analysis
7.3.1 Amega – Biosimilar Products
7.3.2 Amega Biotech Biosimilars Pipeline & Future Strategies
7.4 Other Biosimilars Companies in South America
7.4.1 Bionovis – Company Overview & Analysis
7.4.2 Orygen Biotecnologia – Company Overview & Analysis
7.4.3 Recepta – Company Overview & Analysis
8. Leading Biosimilar Manufacturers in the Rest of the World, 2016
8.1 Celltrion – Company Overview & Analysis
8.1.1 Celltrion Biosimilar Products
8.1.2 Celltrion Biosimilars Pipeline & Future Strategies
8.1.2.1 Trastuzumab Biosimilar
8.1.2.2 Rituximab Biosimilar
8.1.2.3 Four Further Development mAb Biosimilar
8.2 LG Life Sciences – Company Overview & Analysis
8.2.1 LG Life Sciences Biosimilar Products
8.2.2 LG Life Science Biosimilars Pipeline & Future Strategies
8.3 Dong-A – Company Overview & Analysis
8.3.1 Dong-A Biosimilar Products
8.3.2 Dong-A Biosimilars Pipeline & Future Strategies
8.3.2.1 DA-3803 – hCG Biosimilar
8.3.2.2 DA-3031 – Pegylated Filgrastim Biosimilar
8.3.2.3 DA-3880 – Darbepoetin Alpha Biosimilar
8.3.2.4 DA-3111 – Trastuzumab Biosimilar
8.3.2.5 DA-3113 – Adalimumab Biosimilar
8.3.2.6 3853 – Etanercept Biosimilar
8.3.2.7 DA-3808 – Recombinant Factor VIII Biosimilar
8.4 Bioton – Company Overview & Analysis
8.4.1 Bioton’s Biosimilar Products
8.4.2 Bioton’s Biosimilars Pipeline & Future Strategies
8.5 Biocad – Company Overview & Analysis
8.5.1 Biocad’s Biosimilar Products
8.5.2 Biocad’s Biosimilars Pipeline & Future Strategies
8.6 Other Biosimilars Companies in the RoW
8.6.1 Gedeon-Richter – Company Overview & Analysis
8.6.2 Egis Pharmaceuticals – Company Overview & Analysis
8.6.3 JCR Pharmaceuticals – Company Overview & Analysis
8.6.4 Nippon Kayaku – Company Overview & Analysis
8.6.5 Fujifilm Kyowa Kirin Biologics – Company Overview & Analysis
8.6.6 Daiichi Sankyo – Company Overview & Analysis
9. Qualitative Analysis of Biosimilars Market, 2016-2026
9.1 SWOT Analysis of the Global Biosimilars Industry and Market, 2016-2026
9.1.1 Strengths
9.1.1.1 Savings in Healthcare Costs
9.1.1.2 Strong Pipeline – Innovation and Growth of the Biosimilars Market
9.1.1.3 Entry of Biosimilars Into the US market
9.1.2 Weaknesses
9.1.2.1 R&D Cost – Pricing Companies Out of Biosimilars?
9.1.2.2 Developing Market – Biosimilars Still Niche
9.1.2.3 Unclear Regulations for Biosimilars
9.1.3 Opportunities
9.1.3.1 Patent Expiry for Branded Biologics
9.1.3.2 Increase in Prevalence of Chronic Diseases
9.1.3.3 Innovation – New Technology Driving Biosimilar Growth
9.1.3.4 Focus on Biosimilar Monoclonal Antibodies and Insulin
9.1.4 Threats
9.1.4.1 Stricter Regulations for Biosimilar Manufacturers
9.1.4.2 Lawsuits – Patent Protection from Innovator Biologics
9.1.4.3 Biobetters – Removing the Need for Biosimilars?
9.2 STEP Analysis of the Global Biosimilars Industry and Market: 2016 -2026
9.2.1 Social Factors
9.2.1.1 Global Healthcare – An Ambitious Aim?
9.2.1.2 Raising Awareness will Lead to Greater Product Adoption
9.2.2 Technological Factors
9.2.2.1 Innovation Driven – Growing Manufacturing Efficiency
9.2.2.2 High Technological Expertise Needed
9.2.3 Economic Factors
9.2.3.1 R&D for Biosimilar Development – Cost Barriers
9.2.3.2 Healthcare Savings – Cutting Spending and Costs
9.2.4 Political Factors
9.2.4.1 Government Influence – Funding for Biosimilar Industry?
9.2.4.2 International Cooperation Required
9.2.4.3 Regularly Updated Guideline Will Benefit Developers
10. Research Interviews
10.1 Mr Chandru Chawla, Head of Corporate Strategy, Cipla
10.1.1 Cipla Overview
10.1.2 Introducing Cipla’s Biosimilars Landscape
10.1.3 Cipla’s Biosimilars Strategy: Collaboration & Competition
10.1.4 Future Directions for the Biosimilars Industry
10.2 Mr Peter Keller, Chief Business Officer, Selecta Bioscience
10.2.1 Novel Technology Platform
10.2.2 Application with Drugs
10.2.3 Biosimilar Vaccines – Future Potential?
10.2.4 Future Strategies
10.2.5 Biosimilar Market Outlook
10.3 Industry Source from a Leading Indian Biopharmaceutical Company
10.3.1 Indian Pharmaceutical and Biosimilars Market Overview
10.3.2 Indian Patent Protection – Effect on Biosimilar Industry
10.3.3 Partnerships among Biosimilar Companies
10.3.4 Future Developments in the Indian Biosimilars Market
11. Conclusions
11.1 Market Leaders Among Biosimilar Manufacturers
11.2 Will Sandoz Retain its Position as Market Leader?
11.3 Which Companies Are Best Placed to Lead in Future?
11.4 Big Pharma Companies Will Try Gain Market Entry
11.5 Contribution of Chinese and Indian Companies will Grow
11.6 Strong R&D Pipeline – Driver for Growth
11.7 Concluding Remarks
【レポート販売概要】
■ タイトル：世界のトップ25バイオシミラー（バイオ後続品）メーカー分析2016-2026■ 英文：Pharma Leader Series: 25 Top Biosimilar Drug Manufacturers 2016-2026
■ 発行日：2016年4月
■ 調査会社：visiongain
■ 商品コード：VGAIN6041543
■ 調査対象地域：グローバル
- 化粧品用顔料の世界市場予測：無機顔料、有機顔料The global cosmetic pigments market, in terms of value, is projected to reach USD 11.57 Billion by 2021, at a CAGR of 7.2%, from 2016 to 2021. High-growth application in the cosmetics & personal care industry and rapid growth of the facial makeup and eye makeup products are the key factors driving the growth of the global cosmetic pigments market. Cosmetic pigments of superior quality are used to …
- アルミ箔パッケージ材料の世界市場2015-2019About Aluminum Foil Packaging Aluminum foil packaging material is a part of the flexible packaging material and is basically produced using aluminum sheets. Aluminum foil can be used to wrap around any product for packaging purposes. It is manufactured through the continuous casting and cold rolling. The major end-users of aluminum foil are the Pharmaceuticals, and Food and Beverages industries. T …
- Denbury Resources Inc.社の石油・ガス開発・生産動向及びコスト分析（2013年第4四半期）Denbury Resources Inc. Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2013 Summary Denbury Resources Inc. Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential sour …
- 世界の幹細胞抗がん治療市場動向（2012-2016）TechNavio's analysts forecast the Global Stem Anticancer Therapeutics market to grow at a CAGR of 11.48 percent over the period 2012-2016. Increasing investment in R&D is one of the key factors contributing to this market growth. The Global Stem Anticancer Therapeutics market has also been witnessing an increasing number of strategic alliances among vendors. However, stringent regulatory approval …
- 不揮発性メモリの世界市場：フラッシュ、NVSRAM、3D NAND、3D Xpoint、NRAM、FRAM、MRAM、NVDIMMNon-volatile memory market is expected to be worth USD 80.54 Billion by 2022, growing at an estimated CAGR of 9.93% between 2016 and 2022. The major drivers for the growth are the growing need for low cost, longer retention, and high performance memory devices. The rapidly evolving technology, continuous cutback in process, increasing competition, and a fast move toward nanotechnology characterize …
- Razadyne/Reminyl (Alzheimer’s Disease)：市場予測と分析（～2022）Razadyne/Reminyl (Alzheimer’s Disease) - Forecast and Market Analysis to 2022 Summary GlobalData has released its new PharmaPoint Drug Evaluation report, “Razadyne/Reminyl (Alzheimer’s Disease) - Forecast and Market Analysis to 2022”. There are no long-term effective therapies for Alzheimer’s Disease (AD), so this remains at the top of the list for unmet needs. While physicians agree that symptoma …
- オフショア・デコミッショニング（廃止）の世界市場予測（～2025年）“The offshore decommissioning market is projected to grow at a CAGR of 5.05%, from 2017 to 2025.” The offshore decommissioning market is projected to reach USD 8.76 billion by 2025, growing at a CAGR of 5.05%, from 2017 to 2025. Offshore decommissioning is plugging the oil and gas wells which are matured and are non-productive. Maturing oil and gas fields and aging infrastructure in the North Sea …
- 紫外線殺菌装置の世界市場2016-2020About Ultraviolet Disinfection Equipment Ultraviolet irradiation provides effective and rapid inactivation of micro-organisms. The reproduction process and lifecycle of bacteria, viruses, and protozoa can be altered by exposure to germicidal wavelengths of ultraviolet light. Ultraviolet rays from the sun have always played significant roles in the earth's atmosphere. The ultraviolet spectrum is hi …
- モデルマウスの世界市場分析・予測（～2021）：近交系モデルマウス、ノックアウトモデルマウス、雑種モデルマウスThe mice model market is expected to reach USD 1.59 Billion in 2021 from USD 1.11 Billion in 2016, growing at a CAGR of 7.5%. Ongoing innovations in mice models, personalized medicine driving the demand for humanized mice models, continuous support in the form of investments and grants, and growing pharmaceutical R&D activities are some of the factors that are expected to drive the growth of the g …
- 世界の移植骨及び骨代用材市場2015The Global Bone Grafts and Substitutes Industry 2015 Market Research Report is a professional and in-depth study on the current state of the Bone Grafts and Substitutes industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure.The Bone Grafts and Substitutes market analysis is provided for the international mark …
- キャップ及びクロージャーの世界市場：プラスチック製（ネジキャップ、分注キャップ）、金属製MarketsandMarkets projects that the caps & closures market size will grow from USD 49.78 Billion in 2015 to USD 68.71 Billion by 2021, at an estimated CAGR of 5.62%. The caps & closures market is expected to witness high growth as a result of the growing end-use industry such as beverage and healthcare as well as the rising concerns toward product quality and safety. Caps & closures seal the conte …
- King Systems Corporation：市場シェア分析King Systems Corporation Market Share Analysis Summary GlobalData’s new report, “King Systems Corporation Market Share Analysis” provides in-depth information on King Systems Corporation’s market position in the airway and anesthesia devices market. The report also provides data and information on the overall competitive landscape within the airway and anesthesia devices market. The report is supp …
- マルチパラメータ患者モニタの世界市場About Multiparameter Patient Monitoring Equipment Multiparameter patient monitoring equipment is a monitoring system that measures and displays the waveforms and numerical data for patients. It is helpful in the diagnosis of disorders/diseases as well as in the treatment of patients in various healthcare settings. This monitoring system is capable of measuring a variety of vital patient parameters …
- 世界の自動車ヘッドアップディスプレイ市場動向（2012-2016）TechNavio's analysts forecast Global Automotive Head-up Display market to grow at a CAGR of 28.61 percent over the period 2012-2016. One of the key factors contributing to this market growth is the Increasing customer awareness about vehicle safety. The Global Automotive Head-up Display market has also been witnessing the increasing penetration of head-up displays in the Mid-range Car segment in t …
- シリコーンの世界市場：タイプ別（エラストマー、流体、樹脂、ゲル、その他）、エンドユーザー別（建築、建設、輸送、パーソナルケア、消費財、エネルギー、電気、電子、紙、繊維、その他）The global silicone market was valued at $18.2 billion in 2018, and is projected to reach $91.4 billion by 2026, growing at a CAGR of 22.5% from 2019 to 2026. Silicone are polymers that are made up of siloxane. Siloxane is a chain of alternating silicon and oxygen atoms combined with carbon or hydrogen. It is a versatile material, owing to its exceptional chemical & mechanical properties, due to w …
